Monte Rosa Therapeutics Inc Aktie News

Monte Rosa secured a second major Novartis deal, adding $120M upfront and up to $5.7B in milestones to its cash reserves. GLUE advances MRT-8102, a NEK7 molecular glue degrader, into Phase 1 trials targeting inflammatory and cardio-immunology disorders, with key data expected in H1 2026. Strong financial position with $295.5M in cash as of June 2025, supported by multiple big pharma collaborati...

Monte Rosa Therapeutics shares jumped this week after the company expanded its collaboration with Novartis. The Novartis partnership brings significant upfront cash and external QuEEN platform validation. Monte Rosa's molecular glue degraders can target previously undruggable proteins.

Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's  growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered ro...

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.

Monte Rosa Therapeutics (GLUE -1.26%), a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The standout news was a sharp jump in GAAP revenue, which reached $23.2 million, well above GAAP expectations of $7.4 million.

Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation of multiple Phase 2 studies in immune-mediated diseases Phase 1/2 study of GSPT1-directe...

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026 Additional Phase 1 cohort designed to evaluate potential early proof of concept in subjects with increased cardiovascular disease (...

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries featured on the cover of Science. The research article, “Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrat...